View Item 

Show simple item record

The Art and Science of Immunosuppression: The Fifth Annual American Society of Transplant Surgeon's State-of-the-Art Winter Symposium

dc.contributor.authorPomfret, Elizabeth A.en_US
dc.contributor.authorFeng, Sandyen_US
dc.contributor.authorHale, D. A.en_US
dc.contributor.authorMagee, John C.en_US
dc.contributor.authorMulligan, M.en_US
dc.contributor.authorKnechtle, S. J.en_US
dc.date.accessioned2010-06-01T18:51:48Z
dc.date.available2010-06-01T18:51:48Z
dc.date.issued2006-02en_US
dc.identifier.citationPomfret, E. A.; Feng, S.; Hale, D. A.; Magee, J. C.; Mulligan, M.; Knechtle, S. J. (2006). "The Art and Science of Immunosuppression: The Fifth Annual American Society of Transplant Surgeon's State-of-the-Art Winter Symposium." American Journal of Transplantation 6(2): 275-280. <http://hdl.handle.net/2027.42/72057>en_US
dc.identifier.issn1600-6135en_US
dc.identifier.issn1600-6143en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72057
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16426311&dopt=citationen_US
dc.format.extent176990 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherMunksgaard International Publishersen_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 The American Society of Transplantation and the American Society of Transplant Surgeonsen_US
dc.titleThe Art and Science of Immunosuppression: The Fifth Annual American Society of Transplant Surgeon's State-of-the-Art Winter Symposiumen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Transplant Surgery, University of Michigan Health Center, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherDepartment of Surgery, Division of Liver Transplantation and Hepatobiliary Surgery, Lahey Clinic Medical Center, Burlington, MA, USAen_US
dc.contributor.affiliationotherDepartment of Surgery, Division of Transplantation, University of California San Francisco, San Francisco, CA, USAen_US
dc.contributor.affiliationotherDepartment of Transplantation NIDDK, National Institutes of Health, Bethesda, MD, USAen_US
dc.contributor.affiliationotherDepartment of Surgery, Division of Thoracic Surgery, University of Washington, Seattle, WA, USAen_US
dc.contributor.affiliationotherDepartment of Surgery, Division of Transplantation, University of Wisconsin Hospital and Clinic, Madison, WI, USAen_US
dc.identifier.pmid16426311en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72057/1/j.1600-6143.2005.01187.x.pdf
dc.identifier.doi10.1111/j.1600-6143.2005.01187.xen_US
dc.identifier.sourceAmerican Journal of Transplantationen_US
dc.identifier.citedreferenceSarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125 – 138.en_US
dc.identifier.citedreferenceHoffmann SC, Pearl JP, Blair PJ, Kirk AD. Immune profiling: molecular monitoring in renal transplantation. Front Biosci 2003; 8: e444 – e462.en_US
dc.identifier.citedreferenceHoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am J Transplant 2005; 5: 573 – 581.en_US
dc.identifier.citedreferenceCoopersmith CM, Brennan DC, Miller B et al. Renal transplantation following previous heart, liver, and lung transplantation: an 8-year single-center experience. Surgery 2001; 130: 457 – 462.en_US
dc.identifier.citedreferenceGonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934 – 1939.en_US
dc.identifier.citedreferenceOjo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931 – 940.en_US
dc.identifier.citedreferenceSarwal MM, Vidhun JR, Alexander SR, Satterwhite T, Millan M, Salvatierra O, Jr. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003; 76: 1331 – 1339.en_US
dc.identifier.citedreferenceCantarovich D. Prevention of acute rejection with antithymocyte globulin (thymoglobuline): its potential to reduce corticosteroids. J Nephrol 2004; 17 ( Suppl 8 ): S40 – S46.en_US
dc.identifier.citedreferenceEason JD, Nair S, Cohen AJ, Blazek JL, Loss GE, Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75: 1396 – 1399.en_US
dc.identifier.citedreferenceFilipponi F, Callea F, Salizzoni M et al. Double-blind comparison of hepatitis C histological recurrence Rate in HCV+ Liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine. Transplantation 2004; 78: 1488 – 1495.en_US
dc.identifier.citedreferenceNeuhaus P, Clavien PA, Kittur D et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8: 132 – 142.en_US
dc.identifier.citedreferenceTzakis AG, Tryphonopoulos P, Kato T et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004; 77: 1209 – 1214.en_US
dc.identifier.citedreferenceMarcos A, Eghtesad B, Fung JJ et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004; 78: 966 – 971.en_US
dc.identifier.citedreferenceCosimi AB, Sachs DH. Mixed chimerism and transplantation tolerance. Transplantation 2004; 77: 943 – 946.en_US
dc.identifier.citedreferenceTakemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033 – 1041.en_US
dc.identifier.citedreferenceChantranuwat C, Qiao JH, Kobashigawa J, Hong L, Shintaku P, Fishbein MC. Immunoperoxidase staining for C4d on paraffin-embedded tissue in cardiac allograft endomyocardial biopsies: comparison to frozen tissue immunofluorescence. Appl Immunohistochem Mol Morphol 2004; 12: 166 – 171.en_US
dc.identifier.citedreferenceMontgomery RA, Hardy MA, Jordan SC et al. Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols. Transplantation 2004; 78: 181 – 185.en_US
dc.identifier.citedreferenceTerasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438 – 443.en_US
dc.identifier.citedreferenceMaier S, Tertilt C, Chambron N et al. Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-/- mice. Nat Med 2001; 7: 557 – 562.en_US
dc.identifier.citedreferenceEisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847 – 858.en_US
dc.identifier.citedreferenceKeogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694 – 2700.en_US
dc.identifier.citedreferenceBriggs D, Dudley C, Pattison J et al. Effects of immediate switch from cyclosporine microemulsion to tacrolimus at first acute rejection in renal allograft recipients. Transplantation 2003; 75: 2058 – 2063.en_US
dc.identifier.citedreferenceSarahrudi K, Estenne M, Corris P et al. International experience with conversion from cyclosporine to tacrolimus for acute and chronic lung allograft rejection. J Thorac Cardiovasc Surg 2004; 127: 1126 – 1132.en_US
dc.identifier.citedreferenceBerenguer M, Prieto M, Rayon JM et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32 ( 4 Pt 1 ): 852 – 858.en_US
dc.identifier.citedreferenceSheiner PA, Schwartz ME, Mor E et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30 – 34.en_US
dc.identifier.citedreferenceRosen HR, Shackleton CR, Higa L et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92: 1453 – 1457.en_US
dc.identifier.citedreferenceBerenguer M, Prieto M, Cordoba J et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol 1998; 28: 756 – 763.en_US
dc.identifier.citedreferenceCharlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5 ( 4 Suppl 1 ): S107 – S114.en_US
dc.identifier.citedreferenceLake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63 – S66.en_US
dc.identifier.citedreferenceBrillanti S, Vivarelli M, De Ruvo N et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884 – 888.en_US
dc.identifier.citedreferenceBerenguer M, Crippin J, Gish R et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34 – 41.en_US
dc.identifier.citedreferenceRegev A, Moura R, Molina E et al. Reliability of histopathological assessment for the differentiation of recurrent hepatitis C from acute cellular rejection post liver transplantation. Hepatology 2003; 38: 277.en_US
dc.identifier.citedreferenceKlaus G, Mostert K, Reckzeh B, Mueller TF. Phenotypic changes in lymphocyte subpopulations in pediatric renal-transplant patients after T-cell depletion. Transplantation 2003; 76: 1719 – 1724.en_US
dc.identifier.citedreferenceLarsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434 – 438.en_US
dc.identifier.citedreferenceWood KJ, Luo S, Akl A. Regulatory T cells: potential in organ transplantation. Transplantation 2004; 77 ( 1 Suppl ): S6 – S8.en_US
dc.identifier.citedreferenceYopp AC, Krieger NR, Ochando JC, Bromberg JS. Therapeutic manipulation of T cell chemotaxis in transplantation. Curr Opin Immunol 2004; 16: 571 – 577.en_US
dc.identifier.citedreferenceLenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992; 257: 789 – 792.en_US
dc.identifier.citedreferenceZheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503 – 514.en_US
dc.identifier.citedreferenceMandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346 – 349.en_US
dc.identifier.citedreferenceMatloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004; 427: 355 – 360.en_US
dc.identifier.citedreferenceBorie DC, Changelian PS, Larson MJ et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005; 79: 791 – 801.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1600-6143.2005.01187.x.pdf
Size:
172.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.